AngioDynamics, Inc. (NASDAQ:ANGO) Receives $18.67 Consensus Price Target from Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $18.6667.

A number of brokerages have commented on ANGO. Canaccord Genuity Group decreased their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Finally, Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th.

AngioDynamics Trading Down 0.9%

Shares of ANGO stock opened at $11.10 on Thursday. AngioDynamics has a 1 year low of $8.36 and a 1 year high of $13.99. The firm’s 50 day moving average is $10.82 and its 200-day moving average is $11.49. The firm has a market capitalization of $458.64 million, a price-to-earnings ratio of -14.80 and a beta of 0.43.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $78.42 million for the quarter, compared to analysts’ expectations of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. On average, equities research analysts forecast that AngioDynamics will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in shares of AngioDynamics by 24.1% during the 1st quarter. SG Americas Securities LLC now owns 37,158 shares of the medical instruments supplier’s stock worth $422,000 after buying an additional 7,220 shares during the period. Hsbc Holdings PLC lifted its holdings in AngioDynamics by 128.4% in the fourth quarter. Hsbc Holdings PLC now owns 62,367 shares of the medical instruments supplier’s stock valued at $801,000 after buying an additional 35,062 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in AngioDynamics by 38.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 14,604 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 4,030 shares during the period. XTX Topco Ltd boosted its stake in AngioDynamics by 69.6% in the fourth quarter. XTX Topco Ltd now owns 40,811 shares of the medical instruments supplier’s stock valued at $524,000 after acquiring an additional 16,742 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in AngioDynamics in the fourth quarter valued at approximately $463,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics sued E2 (Hēlo device) for alleged infringement of its clot-removal patents — a move that could protect ANGO’s IP, limit competitor share gains and potentially secure licensing or damages if successful. Bloomberg Law story MassDevice story
• Neutral Sentiment: Zacks issued a string of small estimate changes: they raised a few out-year/quarter forecasts (Q1 2027 and Q4 2027 modestly, and FY2026 slightly improved) but kept a “Hold” rating. These tweaks are mixed and too small to materially change guidance on their own.
• Negative Sentiment: Zacks cut several near-term EPS forecasts (notably Q2 2028 and Q4 2026) and trimmed Q3 2027 — signaling weaker near-term profitability expectations and contributing to downward pressure on the stock.
• Negative Sentiment: Short interest rose materially in April to ~2.16M shares (about 5.6% of float), up ~18.7% from March, with a ~3.3 days-to-cover — higher shorting can amplify downward moves and indicates increased bearish positioning among traders.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.